|

AL3818 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anlotinib, Catequentenib

Pipeline

Phase 3: 1

Top Sponsors

  • Advenchen Laboratories, LLC1

Indications

  • Alveolar Soft Part Sarcoma1
  • Synovial Sarcoma1
  • Leiomyosarcoma1
  • Soft Tissue Sarcoma1
  • Cancer1

Phoenix, Arizona1 trial

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Mayo Clinic Arizona

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.